Crescita Therapeutics Inc (TO:CTX) — Market Cap & Net Worth
Market Cap & Net Worth: Crescita Therapeutics Inc (CTX)
Crescita Therapeutics Inc (TO:CTX) has a market capitalization of $10.64 Million (CA$14.71 Million) as of September 19, 2026. Listed on the TO stock exchange, this Canada-based company holds position #27005 globally and #1113 in its home market, demonstrating a 5.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crescita Therapeutics Inc's stock price CA$0.79 by its total outstanding shares 18613938 (18.61 Million). Also see Crescita Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Crescita Therapeutics Inc Market Cap History: 2016 to 2026
Crescita Therapeutics Inc's market capitalization history from 2016 to 2026. Data shows change from $15.19 Million to $10.64 Million (-6.25% CAGR). Also see CTX cash generation efficiency for how efficiently the company converts equity into cash flow.
Crescita Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crescita Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CTX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.31x
Crescita Therapeutics Inc's market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.19 Million | $3.50 Million | -$14.95 Million | 4.34x | N/A |
| 2017 | $7.08 Million | $12.01 Million | -$11.46 Million | 0.59x | N/A |
| 2018 | $5.99 Million | $16.63 Million | $2.40 Million | 0.36x | 2.50x |
| 2019 | $12.52 Million | $22.34 Million | $1.85 Million | 0.56x | 6.75x |
| 2020 | $9.43 Million | $15.64 Million | $37.00K | 0.60x | 254.74x |
| 2021 | $8.75 Million | $16.77 Million | -$1.10 Million | 0.52x | N/A |
| 2022 | $8.89 Million | $23.52 Million | $862.00K | 0.38x | 10.31x |
| 2023 | $6.60 Million | $17.52 Million | -$1.99 Million | 0.38x | N/A |
| 2024 | $7.81 Million | $19.58 Million | -$2.75 Million | 0.40x | N/A |
| 2025 | $6.46 Million | $21.12 Million | -$92.00K | 0.31x | N/A |
Competitor Companies of CTX by Market Capitalization
Companies near Crescita Therapeutics Inc in the global market cap rankings as of September 19, 2026. Review CTX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Crescita Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Crescita Therapeutics Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Crescita Therapeutics Inc's market cap moved from $15.19 Million to $ 10.64 Million, with a yearly change of -6.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$10.64 Million | +64.58% |
| 2025 | CA$6.46 Million | -17.24% |
| 2024 | CA$7.81 Million | +18.37% |
| 2023 | CA$6.60 Million | -25.76% |
| 2022 | CA$8.89 Million | +1.54% |
| 2021 | CA$8.75 Million | -7.14% |
| 2020 | CA$9.43 Million | -24.73% |
| 2019 | CA$12.52 Million | +108.99% |
| 2018 | CA$5.99 Million | -15.40% |
| 2017 | CA$7.08 Million | -53.39% |
| 2016 | CA$15.19 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Crescita Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.64 Million USD |
| MoneyControl | $10.64 Million USD |
| MarketWatch | $10.64 Million USD |
| marketcap.company | $10.64 Million USD |
| Reuters | $10.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more